BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2005
 |  BioCentury  |  Politics, Policy & Law

IQWiG's study

IQWiG's study

IQWiG's study
IQWiG's study of the "benefit assessment of statins with special consideration of atorvastatin" was intended to investigate whether atorvastatin, which is still under patent, is superior to other statins for patients with stable coronary heart disease, acute coronary syndrome, or diabetes. IQWiG also asked whether patients taking atorvastatin experienced more side effects, in particular hepatic or myopathic side effects, at the highest recommended dose than did patients treated with other...

Read the full 372 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >